BRAIN, published by Oxford University Press, stands as a preeminent journal in the realms of neurology and medicine, with a formidable impact factor reflecting its rigorous peer-reviewed standards and significant contributions to the field. With its ISSN 0006-8950 and E-ISSN 1460-2156, this esteemed publication spans over a century of exceptional research, converging from its historical roots in 1878 to current groundbreaking studies. BRAIN boasts a distinguished rank of #8 out of 400 in the Scopus category of Neurology (Clinical), placing it in the 98th percentile of institutions, indicative of its influence and reach. Operating under the Q1 category in both Medicine (Miscellaneous) and Clinical Neurology, the journal is dedicated to fostering interdisciplinary dialogue among researchers, clinicians, and students alike. With a focus on innovative findings and clinical advancements, BRAIN serves as a vital resource for those seeking to deepen their understanding of neurological disorders and the evolving landscape of medical research.

METABOLIC BRAIN DISEASE, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal dedicated to advancing our understanding of the metabolic processes impacting brain health and disease. Established in 1986 and set to continue until 2024, this journal encompasses a wide range of interdisciplinary research that intersects the fields of Biochemistry, Cellular and Molecular Neuroscience, and Neurology, as evidenced by its notable quartile placements in Q2 and Q3 for 2023. With an ISSN of 0885-7490 and an E-ISSN of 1573-7365, it serves as a vital resource for researchers and practitioners aiming to deepen their insights into cerebral metabolic disorders and their implications. Although currently not an Open Access option, its rigorous peer-review process ensures that high-quality, impactful research reaches its audience. Showcasing a significant rank within the top percentile of its categories, METABOLIC BRAIN DISEASE is instrumental in shaping the future of neurological research and clinical applications.

CEREBRAL CORTEX, published by Oxford University Press Inc, is a premier journal dedicated to advancing the field of neuroscience, specifically focusing on the cellular, molecular, and cognitive aspects of cortical structure and function. With an impressive impact factor that situates it in the top quartile (Q1) of its categories for 2023, this journal holds significant relevance for researchers and professionals interested in the latest discoveries and methodologies in both Cognitive Neuroscience (ranked #31 out of 115) and Cellular and Molecular Neuroscience (ranked #48 out of 97). Operating without an open access model, it ensures rigorous peer review and dissemination of high-quality research from across the globe. Since its inception in 1991, CEREBRAL CORTEX has established itself as a critical platform for educators and inventors, pushing the boundaries of knowledge in understanding brain function and its implications for behavior. Researchers and students alike will find this journal an invaluable resource for both foundational and cutting-edge studies in neuroscience.

The American Journal of Alzheimer's Disease and Other Dementias, published by SAGE Publications Inc, is a pivotal resource for researchers, clinicians, and students engaged in the study of neurodegenerative diseases, particularly Alzheimer’s disease and various forms of dementia. With an impact factor reflecting its significance in the field, the journal boasts an open-access format since 2020, ensuring that groundbreaking research is accessible to a global audience. The journal holds prestigious Q2 rankings across several categories, including Clinical Psychology, Geriatrics and Gerontology, Neuroscience, and Psychiatry and Mental Health. Covering a wide spectrum from 1986 to 2024, it provides essential insights into innovative treatments, care strategies, and the latest findings in dementia research, solidifying its importance in fostering knowledge and advancing the field. With a commitment to high-quality scholarship, this journal is an indispensable tool for advancing understanding in the dynamic landscape of dementia studies.

Journal of Alzheimer's Disease, published by IOS Press, stands as a pivotal resource in the fight against Alzheimer's and related neurodegenerative disorders. With an ISSN of 1387-2877 and an E-ISSN of 1875-8908, this esteemed journal has evolved since its inception in 1998, providing a vital platform for academic research and clinical practice in the realms of Clinical Psychology, Geriatrics and Gerontology, Neuroscience, and Psychiatry and Mental Health. Ranked in the Q1 category across several disciplines, including Clinical Psychology and Geriatrics, this journal not only highlights significant advancements in understanding Alzheimer's disease but also fosters interdisciplinary dialogue among researchers, healthcare professionals, and policymakers. Boasting robust Scopus rankings—such as 49th in Clinical Psychology and 29th in Geriatrics—this journal is committed to disseminating high-quality research that informs both therapeutic strategies and public health initiatives. The Journal of Alzheimer's Disease is an essential resource for anyone dedicated to exploring the complexities of cognitive decline and enhancing care for affected individuals.

Aging Clinical and Experimental Research, published by Springer, is a premier journal dedicated to advancing the field of geriatric medicine and understanding the complexities of aging. With a commitment to publishing high-quality original research, review articles, and clinical studies, this journal plays a crucial role in disseminating knowledge to researchers, healthcare professionals, and students interested in the biological, clinical, and social aspects of aging. Boasting a 2023 impact factor that places it in the Q2 quartile for both Aging and Geriatrics and Gerontology categories, it ranks favorably within the Scopus metrics—20th out of 116 in Geriatrics and Gerontology and 15th out of 38 in Aging. The journal provides vital insights for the ongoing discourse in aging research, making it an essential resource for those seeking to enhance their understanding of aging-related phenomena and improve healthcare outcomes across populations. The converged years of publication from 1989 to 2024 demonstrate its longstanding commitment to the field, highlighted by its notable presence in Germany and access to a broad international readership.

EXPERIMENTAL AGING RESEARCH, published by Taylor & Francis Inc., is a leading journal that has been at the forefront of aging research since its inception in 1975. With an ISSN of 0361-073X and an E-ISSN of 1096-4657, this journal has earned a notable reputation, including a Q3 ranking in the field of Aging and impressive Q1 and Q2 rankings in Arts and Humanities and Geriatrics and Gerontology respectively. This positions the journal within the top percentile of its category, highlighting its significant impact and contribution to the scientific community. Covering a broad scope that intersects various disciplines, EXPERIMENTAL AGING RESEARCH aims to disseminate pioneering research, foster interdisciplinary collaboration, and provide a platform for innovative studies that enhance understanding of the aging process. While it currently does not offer Open Access, researchers and academics can access its rich repository of knowledge that spans multiple facets of aging, from physiological changes to psychological impacts. As the field of aging continues to evolve, this journal remains an essential resource for researchers, professionals, and students dedicated to advancing knowledge and practices concerning aging and longevity.

Alzheimer's Research & Therapy is a leading peer-reviewed journal published by BMC, dedicated to advancing our understanding of Alzheimer's disease and other neurodegenerative disorders. As an Open Access journal since 2009, it ensures that vital research findings are freely accessible to the global community, facilitating collaboration and innovation in the field. The journal's commitment to quality is evident in its impressive impact factor and its prestigious ranking in the Q1 quartile across multiple categories including Cognitive Neuroscience and Neurology. With a Scopus rank placing it in the top tier of both Neuroscience and Neurology disciplines, Alzheimer's Research & Therapy serves as a crucial platform for researchers, clinicians, and students who seek to contribute to the fight against Alzheimer's and related disorders. The journal covers a wide range of topics and actively encourages submissions that explore therapeutic strategies and innovative research methodologies, enriching the scientific dialogue in this vital area of health.

GeroScience, published by Springer, is an esteemed open-access journal that focuses on the multidisciplinary field of aging research. Since its inception in 2017, the journal has quickly established itself as a leader in its field, achieving impressive Q1 quartile rankings across various categories, including Aging, Cardiology and Cardiovascular Medicine, Geriatrics and Gerontology, and Complementary and Alternative Medicine, as per 2023 evaluations. With a significant impact factor that underscores its influence and reach in academia, GeroScience aims to disseminate high-quality research that addresses the complex challenges and advancements related to aging. Its accessible publication format fosters greater dissemination of knowledge and encourages collaboration among researchers, practitioners, and students eager to contribute to the growing body of work on age-related health issues. As it continues to thrive, GeroScience remains a pivotal resource for anyone looking to stay at the forefront of aging research.

BRAIN RESEARCH is a premier journal published by Elsevier, specializing in the intricate domains of neuroscience, developmental biology, and molecular biology. Established in 1966, this esteemed publication has become a cornerstone for researchers, professionals, and students dedicated to advancing our understanding of brain function and disorders. With an impressive impact factor and a consistent presence in the Q2 quartiles across key categories—such as Developmental Biology, Neurology, and Neuroscience—it stands out as an essential resource for disseminating innovative research and pioneering insights. The journal's scope encompasses both clinical and fundamental studies, fostering a multidisciplinary approach to the complexities of neural systems. Although it is not an open-access journal, BRAIN RESEARCH provides a vital platform for sharing progressive findings that can inspire future studies and contribute significantly to the evolutionary discourse in neuroscience. Based in the Netherlands, at RADARWEG 29, 1043 NX AMSTERDAM, BRAIN RESEARCH continues to shape the landscape of neuroscience research, inviting submissions that explore the latest discoveries and therapeutic strategies.